Manatt’s Ian Spatz, a senior advisor with our Manatt Health team, was interviewed by Bloomberg Law: Health Law & Business for an article on the Trump’s administration’s proposal challenging the pharmaceutical industry.
Senators have come together from both sides of the aisle in support of the administration’s proposal to require drugmakers to disclose list prices. The publication noted that the drug industry is not likely to comply without first fighting back.
Spatz said that drug companies can be expected to contend the federal government does not have the authority to force them to disclose prices in advertisements or to enforce a proposal like this in the first place.